Response by Kazi et al to Letter Regarding Article, "Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy".
作者信息
Kazi Dhruv S, Bellows Brandon K, Spertus John A, Baron Suzanne J, Shen Changyu, Cohen David J, Yeh Robert W, Arnold Suzanne V, Sperry Brett W, Maurer Mathew S, Shah Sanjiv J
机构信息
Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Boston, MA (D.S.K., S.J.B., C.S., R.W.Y.).
Division of Cardiology, Beth Israel Medical Center, Boston, MA(D.S.K., C.S., R.W.Y.).
出版信息
Circulation. 2020 Oct 13;142(15):e212-e213. doi: 10.1161/CIRCULATIONAHA.120.049842. Epub 2020 Oct 12.
Abstract
摘要
相似文献
1
Response by Kazi et al to Letter Regarding Article, "Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy".
Circulation. 2020 Oct 13;142(15):e212-e213. doi: 10.1161/CIRCULATIONAHA.120.049842. Epub 2020 Oct 12.
2
Letter by Rozenbaum et al Regarding Article, "Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy".
Circulation. 2020 Oct 13;142(15):e210-e211. doi: 10.1161/CIRCULATIONAHA.120.046955. Epub 2020 Oct 12.
3
Response by Elliott et al to Letter Regarding Article, "Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy".
Circ Heart Fail. 2022 Jul;15(7):e009637. doi: 10.1161/CIRCHEARTFAILURE.122.009637. Epub 2022 Jun 24.
4
Letter by Baldovino et al Regarding Article, "Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy".
Circ Heart Fail. 2022 Jul;15(7):e009617. doi: 10.1161/CIRCHEARTFAILURE.122.009617. Epub 2022 Jun 24.
5
Tafamidis in the Treatment of ATTR-related Cardiomyopathy: Indications and Grey Zones.
Heart Fail Clin. 2024 Jul;20(3):333-341. doi: 10.1016/j.hfc.2024.03.007. Epub 2024 Apr 12.
6
Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy.
Circulation. 2020 Apr 14;141(15):1214-1224. doi: 10.1161/CIRCULATIONAHA.119.045093. Epub 2020 Feb 12.
7
Redefining Prognosis of Transthyretin Cardiomyopathy in the Tafamidis Era.
J Card Fail. 2022 Oct;28(10):1519-1521. doi: 10.1016/j.cardfail.2022.08.003. Epub 2022 Aug 18.
8
Longitudinal evolution of ventricular function and cardiac magnetic resonance imaging tissue characteristics in tafamidis-treated transthyretin amyloid cardiomyopathy.
Amyloid. 2024 Jun;31(2):145-147. doi: 10.1080/13506129.2023.2284108. Epub 2023 Dec 9.
9
Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
Circ Heart Fail. 2015 May;8(3):519-26. doi: 10.1161/CIRCHEARTFAILURE.113.000890. Epub 2015 Apr 14.
10
Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
Am J Cardiol. 2021 Jun 1;148:146-150. doi: 10.1016/j.amjcard.2021.02.035. Epub 2021 Mar 3.
本文引用的文献
1
Reforming the Orphan Drug Act for the 21st Century.
N Engl J Med. 2019 Jul 11;381(2):106-108. doi: 10.1056/NEJMp1902943.
2
QALYs in 2018-Advantages and Concerns.
JAMA. 2018 Jun 26;319(24):2473-2474. doi: 10.1001/jama.2018.6072.
3
The economics of heart failure.
Heart Fail Clin. 2013 Jan;9(1):93-106. doi: 10.1016/j.hfc.2012.09.005.
4
Incorporating societal concerns for fairness in numerical valuations of health programmes.
Health Econ. 1999 Feb;8(1):25-39. doi: 10.1002/(sici)1099-1050(199902)8:1<25::aid-hec398>3.0.co;2-h.
Zotero 插件